BDBM418791 N-methyl-N-{3-[({2-[(4-morpholin-4- ylphenyl)amino]-5- (trifluoromethyl)pyrimidin-4- yl}amino)methyl]pyridin-2- yl}methanesulfonamide (291), hydrochloride salt::US10450297, Example 291
SMILES: CN(c1ncccc1CNc1nc(Nc2ccc(cc2)N2CCOCC2)ncc1C(F)(F)F)S(C)(=O)=O
InChI Key: InChIKey=XHPUQAFRUACYDR-UHFFFAOYSA-N
Data: 1 IC50
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Focal adhesion kinase 1 [410-689] (Homo sapiens (Human)) | BDBM418791 (N-methyl-N-{3-[({2-[(4-morpholin-4- ylphenyl)amino...) | PDB MMDB NCI pathway Reactome pathway KEGG B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <0.595 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer HealthCare Pharmaceuticals Corporation | Assay Description The in vitro activity of the compounds of the compounds of the invention may be determined by the following procedure. More particularly, the followi... | J Med Chem 50: 984-1000 (2007) BindingDB Entry DOI: 10.7270/Q2T72KQP | |||||||||||
More data for this Ligand-Target Pair |